Xia Pingping, Pan Yundan, Zhang Fan, Wang Na, Wang E, Guo Qulian, Ye Zhi
Cell Physiol Biochem. 2018;45(6):2351-2368. doi: 10.1159/000488183. Epub 2018 Mar 13.
BACKGROUND/AIMS: Recent researches highlighted the protective potential of pioglitazone, a PPAR-γ agonist, in the progression of cerebral ischemia-reperfusion injury. However, there has been no study on the application of pioglitazone in treating ischemic stroke through mechanisms involving pyroptosis.
The cerebral injury was established by middle cerebral artery occlusion (MCAO). in vitro ischemia in primary cultured astrocytes was induced by the oxygen-glucose deprivation (OGD). ELISA and Western Blot analysis were employed to the levels of PPAR-γ, pyroptosis-related biomarkers and cytoplasmic translocation of HMGB-1 and RAGE expression as well as Rac1 activity, respectively.
We demonstrated that repeated intraperitoneal administration of pioglitazone remarkably reduced the infarct volume, improved neurological deficits and suppressed the Rac1 activity with significant reduction of excessive ROS in rat model of middle cerebral artery occlusion (MCAO). Moreover, pioglitazone alleviated the up-regulation of pyroptosis-related biomarkers and the increased cytoplasmic translocation of HMGB-1 and RAGE expression in cerebral penumbra cortex. Similarly, the protective effects of pioglitazone on cultured astrocytes were characterized by reduced Rac1 activity, pyroptosis related protein expressions and lactate dehydrogenase (LDH) release. However, these protective effects of pioglitazone were neutralized with the use of GW9662, a PPAR-γ inhibitor. Interestingly, Rac1 knockdown in lentivirus with the Rac1 small hair RNA (shRNA) could inhibit the OGD-induced pyroptosis of primary cultured astrocytes. Furthermore, the combination of Rac1-shRNA and pioglitazone can further strengthen the inhibitory effects on pyroptosis induced by OGD.
The neuroprotection of pioglitazone was attributable to the alleviated ischemia/hypoxia-induced pyroptosis and was also associated with the PPARγ-mediated suppression of HGMB-1/RAGE signaling pathway. Moreover, the inhibition of Rac1 promoted this function.
背景/目的:近期研究突显了吡格列酮(一种PPAR-γ激动剂)在脑缺血再灌注损伤进展中的潜在保护作用。然而,尚无关于吡格列酮通过焦亡机制治疗缺血性中风的应用研究。
通过大脑中动脉闭塞(MCAO)建立脑损伤模型。采用氧糖剥夺(OGD)诱导原代培养星形胶质细胞发生体外缺血。分别用ELISA和蛋白质免疫印迹分析PPAR-γ水平、焦亡相关生物标志物、HMGB-1的细胞质转位和RAGE表达以及Rac1活性。
我们证明,在大脑中动脉闭塞(MCAO)大鼠模型中,重复腹腔注射吡格列酮可显著减小梗死体积、改善神经功能缺损并抑制Rac1活性,同时显著减少过量的活性氧(ROS)。此外,吡格列酮减轻了脑半暗带皮质中焦亡相关生物标志物的上调以及HMGB-1和RAGE表达的细胞质转位增加。同样,吡格列酮对培养的星形胶质细胞的保护作用表现为Rac1活性降低、焦亡相关蛋白表达减少和乳酸脱氢酶(LDH)释放减少。然而,使用PPAR-γ抑制剂GW9662可中和吡格列酮的这些保护作用。有趣的是,用Rac1小发夹RNA(shRNA)的慢病毒敲低Rac1可抑制OGD诱导的原代培养星形胶质细胞焦亡。此外,Rac1-shRNA与吡格列酮联合可进一步增强对OGD诱导的焦亡的抑制作用。
吡格列酮的神经保护作用归因于减轻缺血/缺氧诱导的焦亡,并且还与PPARγ介导的HGMB-1/RAGE信号通路抑制有关。此外,Rac1的抑制促进了该功能。